{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:16:16Z","timestamp":1792088176962,"version":"4.4.0"},"reference-count":45,"publisher":"American Academy of Pediatrics (AAP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2001,8,1]]},"abstract":"\n Background and Objective.<\/jats:title>\n There seems to be a strong causal relationship between allergy and the origins of asthma. Susceptibility to both is determined by a combination of genetics and environment acting through a complex network of cytokines. Nearly 90% of affected children have positive skin tests indicating the presence of specific immunoglobulin E (IgE), with sensitivity to house dust mite, Alternaria, cockroach, cat, and dog most closely linked to the disease. Greater exposure to house dust mite during infancy leads to earlier onset of wheezing, and elevated serum IgE levels correlate with the appearance of asthma symptoms. Specific IgE binds to high-affinity (Fc\u03b5RI) receptors on mast cells and basophils. The IgE-mediated reactions that follow exposure of sensitized mast cells to an allergen are designated early- and late-phase asthmatic responses (EAR and LAR). EAR is characterized by release of histamine and other preformed mediators within 1 hour of allergen exposure. It is often followed by LAR, an infiltration of the airways by inflammatory cells associated with an episode of more prolonged, and usually more severe airflow obstruction, 4 to 8 hours after antigen exposure. Chronic airway symptoms result from persistent LAR caused by continuous allergen exposure. IgE antibodies are capable of passive transfer of both EAR and LAR sensitivity. IgE-mediated mast cell activation contributes to chronic tissue eosinophilia and airway remodeling, with permanent loss in pulmonary function.<\/jats:p>\n Omalizumab (rhuMAb-E25) is a recombinant, humanized, monoclonal anti-IgE antibody of mouse origin developed for the treatment of IgE-mediated diseases. Omalizumab binds to free IgE at the same site as the high-affinity receptor. Although it attaches to free IgE, it does not bind to IgA, IgG, or cell-bound IgE. It therefore does not induce cross-linking of cell-bound IgE, which would lead to the release of allergic mediators. It has been reported to decrease serum IgE levels in a dose-dependent manner, inhibit EAR and LAR, and cause a down-regulation of Fc\u03b5RI receptors on basophils. Omalizumab has been reported to be safe and effective in improving asthma control and reducing the requirement for oral and inhaled corticosteroids. This double-blind, randomized, placebo-controlled study evaluated the safety, steroid-sparing effects, and impact on disease exacerbations of omalizumab in the treatment of childhood asthma.<\/jats:p>\n <\/jats:sec>\n \n Methods.<\/jats:title>\n Participants were 334 males and premenarchal females aged 6 to 12 years, with moderate to severe allergic asthma requiring treatment with inhaled corticosteroids. During a run-in phase, all children were switched to equivalent doses of beclomethasone dipropionate (BDP), and the dose was adjusted to assure maintenance of asthma control achieved with previous corticosteroid treatment. Children were randomized to subcutaneously administered placebo (N = 109) or omalizumab (N = 225) at a dose based on body weight and initial serum IgE (0.016 mg\/kg\/IgE [IU\/mL] per 4 weeks). BDP dose (initial range 168\u2013420 \u03bcg\/d) was kept stable for 16 weeks (stable-steroid phase), reduced over 8 weeks to the minimum effective dose (steroid-reduction phase), and maintained constant for the final 4 weeks.<\/jats:p>\n <\/jats:sec>\n \n Results.<\/jats:title>\n More participants in the omalizumab group decreased their BDP dose, and their reduction was greater than that of the placebo group (median reduction 100% vs 66.7%). BDP was withdrawn completely in 55% of the omalizumab group versus 39% of the placebo group.<\/jats:p>\n The incidence and the frequency of asthma exacerbations requiring treatment with doubling of BDP dose or systemic corticosteroids were lower in the omalizumab group. The treatment differences were statistically significant during the steroid-reduction phase, during which fewer participants in the omalizumab group had asthma exacerbation episodes (18.2% vs 38.5%), and the mean number of episodes per patient was smaller than with placebo (0.42 vs 2.72). Five asthma exacerbations requiring hospitalization all occurred in the placebo group.<\/jats:p>\n Participants' and investigators' global evaluations of treatment effectiveness were more favorable for omalizumab than placebo. Investigators rated effectiveness excellent for 31.5% of the omalizumab group versus 16.3% of the placebo group and good for 44.7% of the omalizumab group versus 32.7% of the placebo group.<\/jats:p>\n There was little change in asthma symptom scores or spirometry measurements during either the stable-steroid or steroid dose-reduction phase, with minimal differences between the treatment groups.<\/jats:p>\n The requirement for rescue medication in the omalizumab group during both the stable-steroid and steroid dose-reduction phases was consistently lower than at baseline. At week 28, the median number of puffs of rescue medication taken daily was 0 in the omalizumab group and 0.46 in the placebo group. The change from baseline was significant in favor of omalizumab.<\/jats:p>\n Over the entire treatment period, patients in the omalizumab group missed a mean of 0.65 school days, compared with a mean of 1.21 days in the placebo group. The mean number of unscheduled medical contacts attributable to asthma-related medical problems was significantly smaller in the omalizumab group than in the placebo group throughout the treatment period (0.15 vs 5.35).<\/jats:p>\n Median reduction in serum free IgE was 95% to 99% among omalizumab patients. Median free IgE ranged from 133 to 790 IU\/mL at baseline and was in the range of 6 to 9 IU\/mL during the treatment period. The dosing scheme used in the trial therefore effectively reduced serum IgE in patients with initial concentrations as high as 1300 IU\/mL. There was no reduction in free IgE in the placebo group.<\/jats:p>\n Omalizumab treatment was well tolerated. There were no serious treatment-related adverse events. The frequency and types of all adverse events were similar in the omalizumab and placebo groups. The majority of adverse events were mild to moderate in severity. No adverse events suggestive of serum sickness or immune complex formation were observed. Study-drug\u2013related adverse events occurred more frequently in the omalizumab group than in the placebo group (6.2% vs 0.9%). Urticaria was reported in 9 omalizumab patients (4%) compared with 1 (0.9%) placebo patient and was mild or moderate in nearly all cases.<\/jats:p>\n <\/jats:sec>\n \n Conclusion.<\/jats:title>\n Treatment with omalizumab is safe in children with asthma. It reduces the requirement for inhaled corticosteroids while protecting against disease exacerbation.<\/jats:p>\n <\/jats:sec>","DOI":"10.1542\/peds.108.2.e36","type":"journal-article","created":{"date-parts":[[2004,8,13]],"date-time":"2004-08-13T19:55:51Z","timestamp":1092426951000},"page":"e36-e36","source":"Crossref","is-referenced-by-count":414,"title":["Treatment of Childhood Asthma With Anti-Immunoglobulin E Antibody (Omalizumab)"],"prefix":"10.1542","volume":"108","author":[{"given":"Henry","family":"Milgrom","sequence":"first","affiliation":[{"name":"From the National Jewish Medical and Research Center, Denver, Colorado;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Berger","sequence":"additional","affiliation":[{"name":"Southern California Research Center, Mission Viejo, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjuli","family":"Nayak","sequence":"additional","affiliation":[{"name":"University of Illinois, Peoria, Illinois;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niroo","family":"Gupta","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals, East Hanover, New Jersey;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Pollard","sequence":"additional","affiliation":[{"name":"Allergy & Asthma Research Institute, Louisville, Kentucky; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"McAlary","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals, East Hanover, New Jersey;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel Fowler","family":"Taylor","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals, East Hanover, New Jersey;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Rohane","sequence":"additional","affiliation":[{"name":"Schering-Plough Corporation, Kenilworth, New Jersey. (Work was done during tenure at Novartis Pharmaceuticals, East Hanover, New Jersey.)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2001,8,1]]},"reference":[{"key":"2021121006113894100_B1","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/archpedi.154.3.287","article-title":"Prevalence, impact, and trends in childhood disability due to asthma.","volume":"154","author":"Newacheck","year":"2000","journal-title":"Arch Pediatr Adolesc Med"},{"key":"2021121006113894100_B2"},{"key":"2021121006113894100_B3","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1172\/JCI8272","article-title":"Early life origins of asthma.","volume":"104","author":"Gern","year":"1999","journal-title":"J Clin Invest"},{"key":"2021121006113894100_B4","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/0091-6749(92)90130-T","article-title":"The association of individual allergen reactivity with respiratory disease in a national sample: data from the second National Health and Nutrition Examination Survey, 1976\u201380 (NHANES II).","volume":"90","author":"Gergen","year":"1992","journal-title":"J Allergy Clin Immunol"},{"key":"2021121006113894100_B5","first-page":"59","article-title":"Epidemiology of allergic disease and allergen skin test reactivity in the US population: data from the second National Health and Nutrition Examination Survey (1976\u20131980)-NHANES II.","volume":"85","author":"Turkeltaub","year":"1992","journal-title":"Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M"},{"key":"2021121006113894100_B6"},{"key":"2021121006113894100_B7","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S0091-6749(99)70287-3","article-title":"The relationships among environmental allergen sensitization, allergen exposure, pulmonary function, and bronchial hyperresponsiveness in the Childhood Asthma Management Program.","volume":"104","author":"Nelson","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"2021121006113894100_B8","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1056\/NEJM199008233230802","article-title":"Exposure to house-dust mite allergen (Der p I) and the development of asthma in childhood. A prospective study.","volume":"323","author":"Sporik","year":"1990","journal-title":"N Engl J Med"},{"key":"2021121006113894100_B9","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/0091-6749(89)90100-0","article-title":"Epidemiology of acute asthma: IgE antibodies to common inhalant allergens as a risk factor for emergency room visits.","volume":"83","author":"Pollart","year":"1989","journal-title":"J Allergy Clin Immunol"},{"key":"2021121006113894100_B10","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1034\/j.1398-9995.1999.00085.x","article-title":"Role of IgE in the development of allergic airway inflammation and airway hyperresponsiveness\u2014a murine model.","volume":"54","author":"Hamelmann","year":"1999","journal-title":"Allergy"},{"key":"2021121006113894100_B11","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev.immunol.17.1.255","article-title":"Immunologic basis of antigen-induced airway hyperresponsiveness.","volume":"17","author":"Wills-Karp","year":"1999","journal-title":"Annu Rev Immunol"},{"key":"2021121006113894100_B12","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0091-6749(99)70110-7","article-title":"Total serum IgE and its association with asthma symptoms and allergic sensitization among children.","volume":"104","author":"Sherrill","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"2021121006113894100_B13","doi-asserted-by":"crossref","first-page":"26368","DOI":"10.1016\/S0021-9258(18)47203-1","article-title":"The binding site on human immunoglobulin E for its high affinity receptor.","volume":"269","author":"Presta","year":"1994","journal-title":"J Biol Chem"},{"key":"2021121006113894100_B14"},{"key":"2021121006113894100_B15"},{"key":"2021121006113894100_B16","first-page":"1","article-title":"The inflammatory basis of asthma and its implications for drug treatment.","volume":"26","author":"Holgate","year":"1996","journal-title":"Clin Exp Allergy"},{"key":"2021121006113894100_B17","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/0952-7915(93)90111-5","article-title":"The late phase response: role of IgE, its receptor, and cytokines.","volume":"5","author":"Zweiman","year":"1993","journal-title":"Curr Opin Immunol"},{"key":"2021121006113894100_B18","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1172\/JCI8205","article-title":"IgE in asthma and atopy: cellular and molecular connections.","volume":"104","author":"Oettgen","year":"1999","journal-title":"J Clin Invest"},{"key":"2021121006113894100_B19","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1067\/mai.2000.106485","article-title":"The diverse potential effector and immunoregulatory roles of mast cells in allergic disease.","volume":"105","author":"Williams","year":"2000","journal-title":"J Allergy Clin Immunol"},{"key":"2021121006113894100_B20","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1159\/000237010","article-title":"Inhibition of allergic reactions with antibodies to IgE.","volume":"107","author":"Shields","year":"1995","journal-title":"Int Arch Allergy Immunol"},{"key":"2021121006113894100_B21","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0952-7915(97)80182-3","article-title":"Therapeutic potential of anti-IgE antibodies.","volume":"9","author":"Heusser","year":"1997","journal-title":"Curr Opin Immunol"},{"key":"2021121006113894100_B22","first-page":"859","article-title":"Multiple administrations of the anti-IgE recombinant humanized monoclonal antibody E25 (rhuMAb-E25) reduces free IgE levels in a dose dependent manner in adolescents and children with moderate to severe allergic asthma [abstract no. 57].","volume":"36","author":"Bisberg","year":"1996","journal-title":"J Clin Pharmacol"},{"key":"2021121006113894100_B23","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1164\/ajrccm.155.6.9196083","article-title":"Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response.","volume":"155","author":"Boulet","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"2021121006113894100_B24","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/72601","article-title":"The pharmacological basis of anti-IgE therapy.","volume":"18","author":"Chang","year":"2000","journal-title":"Nat Biotechnol"},{"key":"2021121006113894100_B25","first-page":"231","article-title":"Corticosteroid (CS) withdrawal in a study of recombinant humanized monoclonal antibody to IgE (rhuMAb-E25) [abstract no. 960].","volume":"101","author":"Metzger","year":"1998","journal-title":"J Allergy Clin Immunol"},{"key":"2021121006113894100_B26","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1164\/ajrccm.155.6.9196082","article-title":"The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects.","volume":"155","author":"Fahy","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"2021121006113894100_B27","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.4049\/jimmunol.158.3.1438","article-title":"Down-regulation of FceRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody.","volume":"158","author":"MacGlashan","year":"1997","journal-title":"J Immunol"},{"key":"2021121006113894100_B28","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJM199912233412603","article-title":"Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb- E25 Study Group.","volume":"341","author":"Milgrom","year":"1999","journal-title":"N Engl J Med"},{"key":"2021121006113894100_B29"},{"key":"2021121006113894100_B30","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0091-6749(97)70202-1","article-title":"Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis.","volume":"100","author":"Casale","year":"1997","journal-title":"J Allergy Clin Immunol"},{"key":"2021121006113894100_B31","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0091-6749(72)90113-3","article-title":"Standardization and stability of immunoglobulin E (IgE).","volume":"49","author":"Bazartal","year":"1972","journal-title":"J Allergy Clin Immunol"},{"key":"2021121006113894100_B32","first-page":"164","article-title":"Screening for IgE-mediated allergy.","volume":"16","author":"Merrett","year":"1993","journal-title":"J Clin Immunoassay"},{"key":"2021121006113894100_B33","first-page":"351","article-title":"On the combination of independent two-sample tests of Wilcoxon.","volume":"37","author":"Van Elteren","year":"1960","journal-title":"Bull Int Stat Inst"},{"key":"2021121006113894100_B34","first-page":"5","article-title":"Statistical methods in cancer research. Volume I\u2013The analysis of case- control studies.","volume":"32","author":"Breslow","year":"1980","journal-title":"IARC Sci Publ"},{"key":"2021121006113894100_B35","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1164\/ajrccm\/140.5.1325","article-title":"Prognosis of asthma from childhood to adulthood.","volume":"140","author":"Gerritsen","year":"1989","journal-title":"Am Rev Respir Dis"},{"key":"2021121006113894100_B36","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1056\/NEJM199501193320301","article-title":"Asthma and wheezing in the first six years of life. The Group Health Medical Associates.","volume":"332","author":"Martinez","year":"1995","journal-title":"N Engl J Med"},{"key":"2021121006113894100_B37","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1067\/mai.2000.108310","article-title":"Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis.","volume":"106","author":"Adelroth","year":"2000","journal-title":"J Allergy Clin Immunol"},{"key":"2021121006113894100_B38","first-page":"1000","article-title":"Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys.","volume":"279","author":"Fox","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"2021121006113894100_B39","doi-asserted-by":"crossref","first-page":"10474","DOI":"10.1021\/bi00033a020","article-title":"Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE.","volume":"34","author":"Liu","year":"1995","journal-title":"Biochemistry"},{"key":"2021121006113894100_B40","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0954-6111(94)90044-2","article-title":"Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children.","volume":"88","author":"Agertoft","year":"1994","journal-title":"Respir Med"},{"key":"2021121006113894100_B41","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1056\/NEJM199409153311103","article-title":"Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma.","volume":"331","author":"Haahtela","year":"1994","journal-title":"N Engl J Med"},{"key":"2021121006113894100_B42","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1378\/chest.108.5.1228","article-title":"Effect of early vs late intervention with inhaled corticosteroids in asthma.","volume":"108","author":"Selroos","year":"1995","journal-title":"Chest"},{"key":"2021121006113894100_B43","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1183\/09031936.96.09112256","article-title":"Effects of fluticasone propionate on methacholine dose-response curves in nonsmoking atopic asthmatics.","volume":"9","author":"Overbeek","year":"1996","journal-title":"Eur Respir J"},{"key":"2021121006113894100_B44","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3109\/02770909809075664","article-title":"Is fluticasone propionate superior to the other available inhaled steroids?","volume":"35","author":"Spahn","year":"1998","journal-title":"J Asthma"},{"key":"2021121006113894100_B45","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJM200010123431509","article-title":"Asthma, steroids, and growth.","volume":"343","author":"Wohl","year":"2000","journal-title":"N Engl J Med"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/108\/2\/e36\/1164720\/e36.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/108\/2\/e36\/1164720\/e36.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T01:33:30Z","timestamp":1682732010000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/108\/2\/e36\/63882\/Treatment-of-Childhood-Asthma-With-Anti"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,8,1]]},"references-count":45,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2001,8,1]]},"published-print":{"date-parts":[[2001,8,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.108.2.e36","relation":{},"ISSN":["1098-4275","0031-4005"],"issn-type":[{"value":"1098-4275","type":"electronic"},{"value":"0031-4005","type":"print"}],"subject":[],"published":{"date-parts":[[2001,8,1]]}}}